Search Results

Eighteen-month follow-up from pivotal CARTITUDE-1 study, including progression-free-survival data, to be presented at ASCO and EHA Annual Meetings Findings from the Phase 2 CARTITUDE-2 study will be presented for the first time

For World AIDS Day, we look at the groundbreaking strides the company has made—and continues to make—toward a world without the disease.

Further analysis from the Phase 3 ANDROMEDA study presented at the 2021 ASCO Annual Meeting also show doubling rates of organ response with no new safety signals for the first FDA-approved treatment in a rare blood cell disorder

Results at ASCO from Phase 3 TITAN study final analysis confirm survival benefit achieved with the addition of ERLEADA® to androgen deprivation therapy without significant side effect burden

Severe cases of hemolytic disease of the fetus and newborn can be deadly in infants. That’s why Johnson & Johnson is passionate about investigating a promising option for treating the disorder.

Webcast Will Highlight Progress Made to Advance a Healthier World for All and Health for Humanity 2025 Goals Live ESG Investor Update Webcast Scheduled for June 23, 2021 at 8:00 a.m. ET

Results from Phase 1 study of novel GPRC5DxCD3 T-cell redirecting bispecific antibody demonstrate promising clinical activity and support recommended Phase 2 dose

Subcutaneous administration of BCMAxCD3 T-cell redirecting bispecific antibody demonstrated clinical activity and a promising safety profile according to new data at ASCO

· The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p<0.001) vs. treatment with teriflunomide, an active comparator and widely-used first-line oral treatment, in adult patients with relapsing multiple sclerosis, (RMS)1 · The OPTIMUM trial is the first of its kind to compare head-to-head two oral disease modifying treatments (DMTs) in RMS · Approval follows more than 10 years of cumulative data from Phase 2 and Phase 3 studies demonstrating ponesimod’s efficacy and safety1,2,3 · Approval builds on Janssen’s deep-rooted history in neuroscience and reinforces Company commitment to addressing unmet needs for neurological conditions like MS

Late-breaker is one of 20 Janssen abstracts, 16 of which show the safety profile and efficacy of STELARA in treating Crohn’s disease and ulcerative colitis at Digestive Disease Week (DDW) Virtual 2021